Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320293 · ClinicalTrials.gov registry record · NA
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
A NA study of Psoriasis, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01320293 is a NA study of Psoriasis that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 18 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01320293, a NA study of Psoriasis, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. Although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial function are unknown. In this study we want to assess the cardiovascular risks factors, endothelial dysfunction and inflammatory markers before and after treatment of moderate to severe psoriasis with an FDA-approved biologic agent, adalimumab (Humira).
Conditions Studied
Interventions
- DRUG Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Study Locations (1)
North Carolina
- UNC Dermatology Clinical Trials Unit - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01320293
The ClinicalTrials.gov registry entry for NCT01320293 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] is the first listed.
NCT01320293 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01320293 about?
NCT01320293 is a clinical study titled "Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.". Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. Although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial functi...
What is the current status of trial NCT01320293?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2011-03. Estimated completion is 2015-03.
What conditions does trial NCT01320293 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01320293?
The interventions under investigation include: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] (DRUG).
Who is sponsoring clinical trial NCT01320293?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01320293 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
RECRUITING · NA
-
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
RECRUITING · NA
-
A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
RECRUITING · NA
-
Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
RECRUITING · NA
-
Deucravacitinib Adherence Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.